{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:41:06Z","timestamp":1791247266255,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Myopia is the most widespread ocular disorder globally and its prevalence has been increasing over the past decades. Atropine eye drops stand out as the only pharmacological intervention used in clinical practice to control myopia progression. The aim of this study was to explore the effect of 0.01% atropine eye drops on myopia progression. Patients and Methods: Healthy children aged 6\u201312 years with cycloplegic spherical equivalent (SE) from \u22120.5 D to \u22125.0 D and astigmatism \u22641.5 D were included. Myopia progression was assessed by changes in SE and axial length (AL) over 1 year and SE changes 1 year before the study enrollment and during the 1-year follow-up. Adverse events were evaluated based on complaints reported by either parents or the children themselves during follow-up visits. Results: The analysis involved 55 patients in the 0.01% atropine eye drops group and 66 in the control group. After the 1-year follow-up, the change in SE was \u22120.50 (\u22122.25\u20130.50) D in the control group compared to \u22120.50 (\u22121.50\u20130.50) D in the 0.01% atropine group (p = 0.935); AL change was 0.31 (0.18) mm in the control group and 0.29 (0.18) mm in the 0.01% atropine group (p = 0.480). The change in SE was \u22120.68 (\u22122.0\u2013\u22120.25) D\/year before the study and remained similar \u22120.50 (\u22122.25\u20130.25) D over the 1-year follow-up in the control group (p = 0.111); SE change was reduced from \u22121.01 (\u22122.0\u2013\u22120.25) D\/year before the study to \u22120.50 (\u22121.5\u20130.5) D over the 1-year follow-up in the 0.01% atropine group (p &lt; 0.001). In the 0.01% atropine group, ten (16.4%) children experienced mild adverse events, including blurred near vision, ocular discomfort, photophobia, dry eyes, and anisocoria. Conclusions: Compared to the control group, the administration of 0.01% atropine eye drops demonstrated no significant effect on changes in SE and AL over a 1-year follow-up. However, children in the 0.01% atropine group initially experienced higher myopia progression, which decreased with treatment over the course of 1 year. Future studies should explore the long-term effects, rebound effects, potential genetic associations, and efficacy of higher doses of atropine in managing myopia progression.<\/jats:p>","DOI":"10.3390\/medicina60071022","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T08:50:08Z","timestamp":1718959808000},"page":"1022","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study"],"prefix":"10.3390","volume":"60","author":[{"given":"Dovile","family":"Simonaviciute","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 44037 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvydas","family":"Gelzinis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 44037 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kapitanovaite","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences, Kaunas Clinics, 50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-2391","authenticated-orcid":false,"given":"Andrzej","family":"Grzybowski","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Warmia and Mazury, 10-724 Olsztyn, Poland"},{"name":"Institute for Research in Ophthalmology, 60-554 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Zemaitiene","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 44037 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/IAE.0000000000001489","article-title":"Overview of the complications of high myopia","volume":"37","author":"Ikuno","year":"2017","journal-title":"Retina"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children: A network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chierigo, A., Desideri, L.F., Traverso, C.E., and Vagge, A. (2022). The Role of Atropine in Preventing Myopia Progression: An Update. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050900"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood Myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the Treatment of Childhood Myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tsai, H.R., Chen, T.L., Wang, J.H., Huang, H.K., and Chiu, C.J. (2021). Is 0.01% atropine an effective and safe treatment for myopic children? a systemic review and meta-analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173766"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21748","DOI":"10.1038\/s41598-021-00923-1","article-title":"Multicenter Group of Atropine Treatment for Myopia Control (GTAM). A multicenter Spanish study of atropine 0.01% in childhood myopia progression","volume":"11","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2 Myopia Control with Atropine 0.01% Eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1125000","DOI":"10.3389\/fpubh.2023.1125000","article-title":"Effectiveness of myopia control interventions: A systematic review of 12 randomized control trials published between 2019 and 2021","volume":"11","author":"Lanca","year":"2023","journal-title":"Front Public Heal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","article-title":"Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1136","DOI":"10.1111\/aos.14166","article-title":"Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients","volume":"97","author":"Sacchi","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_17","first-page":"182","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","year":"2018","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","article-title":"Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops","volume":"44","year":"2021","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_19","first-page":"e245","article-title":"Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population","volume":"102","author":"Loughman","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"ref_20","first-page":"910","article-title":"Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial","volume":"127","author":"Lee","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"756398","DOI":"10.3389\/fmed.2021.756398","article-title":"Varying Dose of Atropine in Slowing Myopia Progression in Children Over Different Follow-Up Periods by Meta-Analysis","volume":"8","author":"Gan","year":"2022","journal-title":"Front Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00417-021-05254-5","article-title":"A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting","volume":"259","author":"Kaymak","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: A pilot study","volume":"41","author":"Joachimsen","year":"2021","journal-title":"Int. Ophthalmol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:02:31Z","timestamp":1760108551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["medicina60071022"],"URL":"https:\/\/doi.org\/10.3390\/medicina60071022","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}